Neurogene Inc. announced it raised $37.5 Million in an initial filing from an offering of $37.5 Million

Company

Location

About

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare.